» Articles » PMID: 12737533

Disposition of the Flavonoid Quercetin in Rats After Single Intravenous and Oral Doses

Overview
Publisher Informa Healthcare
Specialty Pharmacology
Date 2003 May 10
PMID 12737533
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

The pharmacokinetic and mean time tissue distribution parameters, after a single 50-mg/kg dose of quercetin administered as intravenous bolus, oral solution, and oral suspension, were determined using rat as an animal model. Following intravenous administration, the elimination rate constant and the elimination half-life were found to be 0.0062 min(-1) and 111 min, respectively. Examining the mean time tissue distribution parameters reflected a strong binding affinity of the drug molecules to both plasma and tissue proteins. In addition, the low permeability rate of drug molecules in the peripheral system was demonstrated. Following the oral administration of the drug, the extent of absorption was greater from solution than from suspension. Moreover, the solution showed a shorter Tmax and a higher Cmax than suspension. The absolute bioavailability for the solution was 0.275 and that for suspension was 0.162. The mean residence time (MRT) and the mean absorption time (MAT) were higher for suspension, reflecting the need for dissolving the drug in order to be absorbed. The mean (in-vivo) dissolution time (MDT(in-vivo)) was 34.5 min. Thus, an oral quercetin formulation that can readily form a drug solution in the gastrointestinal tract may enhance the absorption of the drug.

Citing Articles

Controlled SPION-Exosomes Loaded with Quercetin Preserves Pancreatic Beta Cell Survival and Function in Type 2 Diabetes Mellitus.

Zhuang M, Rao L, Chen Y, Xiao S, Xia H, Yang J Int J Nanomedicine. 2023; 18:5733-5748.

PMID: 37849640 PMC: 10578181. DOI: 10.2147/IJN.S422416.


Quercetin and Its Nano-Formulations for Brain Tumor Therapy-Current Developments and Future Perspectives for Paediatric Studies.

Shala A, Arduino I, Salihu M, Denora N Pharmaceutics. 2023; 15(3).

PMID: 36986827 PMC: 10057501. DOI: 10.3390/pharmaceutics15030963.


Nanoparticles Formulation Improves the Antifibrogenic Effect of Quercetin on an Adenine-Induced Model of Chronic Kidney Disease.

Sanchez-Jaramillo E, Gasca-Lozano L, Vera-Cruz J, Hernandez-Ortega L, Gurrola-Diaz C, Bastidas-Ramirez B Int J Mol Sci. 2022; 23(10).

PMID: 35628203 PMC: 9140764. DOI: 10.3390/ijms23105392.


Improved therapeutic efficacy of quercetin-loaded polymeric nanoparticles on triple-negative breast cancer by inhibiting uPA.

Zhou Y, Chen D, Xue G, Yu S, Yuan C, Huang M RSC Adv. 2022; 10(57):34517-34526.

PMID: 35514369 PMC: 9056791. DOI: 10.1039/d0ra04231e.


Tailoring of Selenium-Plated Novasomes for Fine-Tuning Pharmacokinetic and Tumor Uptake of Quercetin: In Vitro Optimization and In Vivo Radiobiodistribution Assessment in Ehrlich Tumor-Bearing Mice.

Aboud H, Hussein A, Zayan A, Makram T, Sarhan M, El-Sharawy D Pharmaceutics. 2022; 14(4).

PMID: 35456709 PMC: 9032182. DOI: 10.3390/pharmaceutics14040875.